Ju Young Kim1, Young Sook Ku2, Hyun Jeong Kim1, Nga Thi Trinh1, Woorim Kim1, Bomi Jeong3, Tae Young Heo3, Myung Koo Lee1, Kyung Eun Lee4. 1. College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea. 2. College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea; Department of Pharmacy, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea. 3. Department of Information and Statistics, Chungbuk National University, Cheongju 28644, Republic of Korea. 4. College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea. Electronic address: kaylee@cbnu.ac.kr.
Abstract
AIM: To examine the effect of oral diabetes medication on the risk of dementia in an elderly cohort with type 2 diabetes. METHODS: This was a population-based cohort study using the Korean National Health Insurance claims data from 2002 to 2013. Elderly subjects (60 years of age or older) with and without type 2 diabetes were included; patients with new-onset type 2 diabetes were further divided into the oral diabetes medication group and no-medication group. RESULTS: Among 278,290 patients with type 2 diabetes, 56,587 developed dementia (20.3%) over 11 years of follow-up. Type 2 diabetes was associated with a 1.69-fold increased risk of dementia (95% CI 1.66-1.72). Among patients with newly diagnosed type 2 diabetes, the risk of dementia was lower in the oral diabetes medication group than in the no-medication group (adjusted hazard ratio [aHR], 0.79; 95% CI 0.77-0.81). Lower risk of dementia was particularly noticeable in all of the combination therapy groups and especially lower in the combination therapy group treated with dipeptidyl peptidase 4 inhibitor (aHR 0.48, 95% CI 0.45-0.51). CONCLUSION: Overall, the use of oral diabetes medication in type 2 diabetes patients significantly decreased the risk of dementia.
AIM: To examine the effect of oral diabetes medication on the risk of dementia in an elderly cohort with type 2 diabetes. METHODS: This was a population-based cohort study using the Korean National Health Insurance claims data from 2002 to 2013. Elderly subjects (60 years of age or older) with and without type 2 diabetes were included; patients with new-onset type 2 diabetes were further divided into the oral diabetes medication group and no-medication group. RESULTS: Among 278,290 patients with type 2 diabetes, 56,587 developed dementia (20.3%) over 11 years of follow-up. Type 2 diabetes was associated with a 1.69-fold increased risk of dementia (95% CI 1.66-1.72). Among patients with newly diagnosed type 2 diabetes, the risk of dementia was lower in the oral diabetes medication group than in the no-medication group (adjusted hazard ratio [aHR], 0.79; 95% CI 0.77-0.81). Lower risk of dementia was particularly noticeable in all of the combination therapy groups and especially lower in the combination therapy group treated with dipeptidyl peptidase 4 inhibitor (aHR 0.48, 95% CI 0.45-0.51). CONCLUSION: Overall, the use of oral diabetes medication in type 2 diabetespatients significantly decreased the risk of dementia.